Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
View Patent ↗Disclosed herein are methods of treating pain using RANK/RANKL antagonists.
1. A method of treating complex regional pain syndrome (CRPS), comprising orally administering an effective amount of ibrutinib to a mammal in need thereof.
2. The method of claim 1 , wherein the mammal is a human being.
3. The method of claim 1 , wherein about 1 mg to about 100 mg of ibrutinib is orally administered daily.
4. The method of claim 2 , wherein about 100 mg to about 600 mg of ibrutinib is orally administered daily.
5. The method of claim 2 , wherein about 100 mg to about 300 mg of ibrutinib is orally administered daily.
6. The method a claim 2 , wherein about 300 mg to about 600 mg of ibrutinib is orally administered daily.
7. The method of claim 2 , wherein about 550 mg to about 600 mg of ibrutinib is orally administered daily.
8. The method of claim 2 , wherein about 560 mg of ibrutinib is orally administered daily.
9. The method of claim 2 , wherein about 400 mg to about 450 mg of ibrutinib is orally administered daily.
10. The method of claim 2 , wherein about 420 mg of ibrutinib is orally administered daily.
11. The method of claim 2 , wherein three divided doses totaling about 420 mg of ibrutinib is orally administered daily.
12. The method of claim 2 , wherein four divided doses totaling at least about 560 mg of ibrutinib is orally administered daily.
13. The method of claim 2 , wherein the human being experiences less pain within 3 months after oral administration of ibrutinib.
14. The method of claim 2 , wherein the CRPS affects an arm.
15. The method of claim 2 , wherein the CRPS affects a leg.
16. The method of claim 2 , wherein the CRPS affects a foot.
17. The method of claim 2 , wherein the CRPS affects a hand.
18. The method of claim 2 , wherein the patient is about 7 years to about 90 years old.
19. The method of claim 1 , wherein the ibrutinib is orally administered daily over a period of about 1 week to about 24 months.
20. The method of claim 19 , wherein the ibrutinib is orally administered once daily.
21. The method of claim 1 , wherein the ibrutinib is orally administered daily for at least about 6 months.
22. The method of claim 21 , wherein the ibrutinib is orally administered once daily.
23. The method of claim 1 , wherein the ibrutinib is orally administered in a capsule, pill, tablet, or troche.
24. The method of claim 1 , wherein the mammal has had CRPS for at least one month.
25. The method of claim 2 , wherein the CRPS is Type I.
26. The method of claim 2 , wherein the CRPS is Type 2.